Article Details
Retrieved on: 2024-05-16 19:57:00
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Roche's CT-388 Phase I trial results, highlighting its efficacy in weight loss and glycemic control through GLP-1/GIP receptor targeting. This ties to biotechnology, obesity management, and diabetes treatment via peptide hormones and poly-agonist peptides.
Article found on: kommunikasjon.ntb.no
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here